These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1471 related articles for article (PubMed ID: 28940194)

  • 1. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
    Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
    J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.
    Fichter CD; Gudernatsch V; Przypadlo CM; Follo M; Schmidt G; Werner M; Lassmann S
    J Mol Med (Berl); 2014 Nov; 92(11):1209-23. PubMed ID: 25091467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
    Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
    Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.
    Zhang Y; Opresko L; Shankaran H; Chrisler WB; Wiley HS; Resat H
    BMC Cell Biol; 2009 Oct; 10():78. PubMed ID: 19878579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
    Shankaran H; Zhang Y; Tan Y; Resat H
    PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
    Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3.
    Friess H; Fukuda A; Tang WH; Eichenberger A; Furlan N; Zimmermann A; Korc M; Büchler MW
    World J Surg; 1999 Oct; 23(10):1010-8. PubMed ID: 10512940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
    Liu B; Chen D; Chen S; Saber A; Haisma H
    Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
    Tanizaki J; Okamoto I; Sakai K; Nakagawa K
    Br J Cancer; 2011 Sep; 105(6):807-13. PubMed ID: 21847121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L; Xiang B; Muthuswamy SK
    Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers.
    Choi B; Cha M; Eun GS; Lee DH; Lee S; Ehsan M; Chae PS; Heo WD; Park Y; Yoon TY
    Elife; 2020 Apr; 9():. PubMed ID: 32267234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
    Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
    Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.